宣泰医药：2025年前三季度净利润约6346万元

Group 1 - The core viewpoint of the article highlights the financial performance of Xuantai Pharmaceutical in Q3 2023, indicating a decline in revenue and net profit compared to the previous year [1] - For the first three quarters of 2025, the company's revenue was approximately 331 million yuan, representing a year-on-year decrease of 8.59% [1] - The net profit attributable to shareholders was about 63.46 million yuan, showing a year-on-year decline of 31.45% [1] - The basic earnings per share were reported at 0.14 yuan, which is a decrease of 33.33% year-on-year [1] Group 2 - As of the report date, Xuantai Pharmaceutical's market capitalization stood at 4.9 billion yuan [2]